Blood pressure (BP) reflects the force of circulating blood against arterial walls. When that force remains abnormally elevated over time, the condition is termed hypertension. Clinically, hypertension is defined using standardized office measurements (typically systolic BP ≥ 130 mmHg or diastolic BP ≥ 80 mmHg in contemporary guidelines, with confirmatory out-of-office measurements often used). Chronic elevation increases afterload, accelerates vascular remodeling, and drives progressive end-organ damage, particularly to the heart, brain, kidneys, and eyes.
Mechanistically, hypertension is rarely a single disease; it is a hemodynamic phenotype produced by multiple interacting pathways. In essential (primary) hypertension, genetic susceptibility interacts with environmental factors such as excess sodium intake, obesity, physical inactivity, alcohol use, and psychosocial stress. Key physiologic contributors include heightened sympathetic nervous system activity, dysregulation of the renin-angiotensin-aldosterone system (RAAS), endothelial dysfunction with reduced nitric oxide bioavailability, increased oxidative stress, and chronic low-grade inflammation. These changes promote vasoconstriction, arterial stiffness, and impaired vascular relaxation. Over time, structural remodeling of small arteries increases peripheral resistance, sustaining the elevated BP state even if the initiating trigger resolves.
Hypertension is important because it is largely asymptomatic until complications occur. The absence of symptoms can delay diagnosis, so screening is essential. Major risks include ischemic heart disease, heart failure, stroke (both ischemic and hemorrhagic), chronic kidney disease, and peripheral arterial disease. Hypertensive retinopathy and aortic aneurysm/dissection risk are also elevated. Risk rises with both the level of BP and the duration of exposure. For individual patients, risk stratification incorporates comorbidities (e.g., diabetes, chronic kidney disease, dyslipidemia), smoking status, age, and evidence of target-organ damage.
Diagnosis requires accurate measurement. Proper cuff size, patient positioning, and repeated readings are critical to avoid misclassification due to “white coat” effect. When uncertainty exists, ambulatory BP monitoring or home BP monitoring can identify sustained hypertension versus white coat hypertension or masked hypertension. Laboratory evaluation and assessment for secondary causes are guided by age of onset, severity, resistant BP, and clinical clues. Common secondary causes include renal parenchymal disease, renal artery stenosis, primary aldosteronism, obstructive sleep apnea, thyroid dysfunction, and medication/substance-related hypertension (e.g., NSAIDs, corticosteroids, sympathomimetics, stimulants).
Treatment is evidence-based and multi-level: lifestyle interventions and pharmacologic therapy tailored to patient characteristics and goals. Lifestyle measures with consistent benefit include dietary sodium reduction, adherence to dietary patterns such as DASH (high in fruits, vegetables, and low-fat dairy; reduced in saturated fat), weight loss for overweight patients, regular aerobic and resistance exercise, moderation of alcohol, and smoking cessation. These interventions can reduce BP by meaningful margins and improve cardiometabolic risk.
When lifestyle alone is insufficient or BP is substantially elevated, antihypertensive medications are indicated. First-line classes commonly include thiazide-like diuretics, ACE inhibitors, angiotensin receptor blockers (ARBs), and calcium channel blockers. The choice depends on comorbidities: ACE inhibitors or ARBs are particularly beneficial in diabetic kidney disease and proteinuric chronic kidney disease; thiazide-like diuretics are effective for many patients and can be useful when volume expansion contributes; calcium channel blockers can be advantageous when arterial stiffness or angina coexists. Combination therapy is often required because hypertension involves multiple pathophysiologic pathways; using complementary mechanisms improves BP control and reduces adverse effects compared with simply escalating a single drug.
Resistant hypertension—BP that remains above goal despite three appropriately dosed agents, ideally including a diuretic—demands systematic evaluation for adherence issues, interfering substances, and secondary causes. Adherence barriers are common and include medication side effects, complexity, cost, and health literacy challenges. Device-assisted or procedural options may be considered in specialized settings, but pharmacologic optimization remains the foundation.
Targets for therapy balance the reduction of cardiovascular risk against tolerability. Excessive lowering can cause dizziness, falls, or renal function deterioration, especially in patients with dehydration or renal artery disease. Follow-up typically involves reassessment after initiation or dose adjustment, monitoring electrolytes and kidney function when RAAS blockers or diuretics are used, and evaluating orthostatic symptoms.
Education and engagement are central. Patients should understand that hypertension is controllable, that adherence is critical even when BP feels “normal,” and that regular monitoring helps confirm effectiveness. Lifestyle changes also reduce progression of vascular remodeling, which is the biological substrate of long-term complications.
Despite public perception that high BP is a minor issue, it is one of the most important modifiable risk factors in medicine. Timely identification, accurate measurement, evaluation for secondary contributors, and guideline-concordant therapy can substantially reduce stroke, myocardial infarction, and kidney failure. Source: Seth Carnes (@seth_man)
Kalos Resident Seth Carnes: @alb_backup Sir, your blood pressure! Sir!. #breaking
— @seth_man May 1, 2026
SHOP AMAZON BEST SELLERS, CLICK TO BUY FROM AMAZON.
SHOP AMAZON BEST SELLERS, CLICK TO BUY FROM AMAZON.
